Claudia Gravekamp, PhD.

Co-founder and principle scientist

Claudia Gravekamp, PhD, is an Associate Professor in the Department of Microbiology and Immunology of Albert Einstein College of Medicine in New York, and member of the Albert Einstein Cancer Center since 2008.

She received her PhD in 1988 in the field of Tumor Immunology at the Erasmus University in Rotterdam, The Netherlands.

From 1987-1993, she served as head of the Laboratory for Leptospirosis at the Royal Tropical Institute in Amsterdam, The Netherlands.

From 1993-1998, she was a Research Fellow/Instructor in Medicine at the Channing Laboratory of Harvard Medical School, Boston, MA, where she gained expertise in the development of bacterial vaccines.

From 1998-2006, she was an Associate Member of the Cancer Therapy and Research Center, in San Antonio, TX, where she began to develop a program aimed at cancer vaccines.

From 2006-2008, she was a Scientist at the California Pacific Medical Center Research Institute in San Francisco, CA, continuing to develop novel therapeutic approaches to cancer utilizing an attenuated bacterium Listeria monocytogenes as selective delivery platform for anti-cancer agents. Her lab was the first in successfully demonstrating that a live attenuated bacterium could be used to deliver therapeutic levels of radioactivity selectively to tumors and metastases.

Very recently, she develop a novel immune therapeutic approach delivering highly immunogenic recall antigens (as an alternative for neoantigens), like tetanus toxoid into tumor cells by Listeria, and simultaneously redirecting the pre-existing memory T cells (generated during childhood vaccinations), to destroy the TT-expressing tumor cells. She has been funded by grants from NIH (RO1/R21/RO3), and private industry, published 76 scientific articles, is reviewer for various scientific journals, and served as reviewer on several NIH/DOD/PCAN study sections.

Christopher Bradley, MS

CEO & Co-FOUNDER

Chris is a serial entrepreneur with a deep passion for building companies that improve human health and wellbeing.

As CEO of Loki, Chris brings over a decade of executive experience founding, funding and operating complex and innovative healthcare businesses.

A son of two physicians, Chris learned from an early age about the untapped potential of digitized medical data. However, though this data provided immense amounts of raw information it did not lead to the deep understanding and knowledge everyone had hoped for.

These insights led him to start Mana Health, an award-winning health data inter-operability startup he led as co-founder and CEO until its acquisition by Comcast in 2018 where he helped lead new initiatives and entity formation.

Chris is a nationally recognized thought leader and innovator and has contributed to healthcare conversations at the White House, the Office of the National Coordinator for Health IT and in other important venues.

Eileen O’Reilly, MD.

Dr. O'Reilly is Section Head for Hepatopancreaticobiliary/ Neuroendocrine Cancers, Gastrointestinal Oncology Service, Co-Director for Medical Initiatives at the David M. Rubenstein Center for Pancreatic Cancer at Memorial Sloan Kettering (MSK) and is an Attending Physician and Member at MSK and Professor of Medicine at Weill Cornell Medical College. Dr. O'Reilly holds the Winthrop Rockefeller Endowed Chair in Medical Oncology. She is the Principal Investigator of multiple trials in pancreas cancer and has authored/co-authored more than 275 articles, editorials and book chapters.

Dr. O'Reilly received her medical degree at Trinity College (Dublin University) in Ireland. She completed her residency training in Ireland and fellowship training at MSK. Dr. O'Reilly's research and clinical activities focus primarily on pancreatic and hepatobiliary malignancies, and her research directions include integration of molecular and genetic-based therapies for the treatment of pancreas cancer along with development of adjuvant and neoadjuvant therapies and identification of biomarkers for therapy selection.

Dr. O'Reilly teaches and mentors junior faculty, oncology fellows, residents and medical/other students and has numerous teaching and other awards. She also chairs several prestigious medical committees.

John McAuliffe, MD, Ph.D., F.A.C.S.

Dr. McAuliffe is a board-certified surgical oncologist, surgeon scientist, and Associate Professor of Surgery at Montefiore Einstein.  He is the program leader of the pancreatic adenocarcinoma research team in the Integrated Imaging Program for Cancer Research at Montefiore Einstein Comprehensive Cancer Center and the pancreatic cancer team leader of the New York Pathology Oncology Group.  He is a high-volume surgeon focusing on pancreatic, gastric, and neuroendocrine malignancies.

Dr. McAuliffe's research focuses on pancreatic adenocarcinoma metastasis and tumor associated macrophages. He is the principal investigator on several projects.  His work has been published in a number of peer-reviewed journals and books and has been presented nationally. He is an active member of numerous professional societies.

Dr. McAuliffe received his Ph.D. at the University of Texas Graduate School of Biomedical Sciences at Houston and his MD from the McGovern Medical School in Houston. His surgical training was at the University of Alabama-Birmingham Hospital and Memorial Sloan Kettering Cancer Center.

Jennifer Chuy, MD

Dr. Chuy is an Attending Physician in hematology and oncology at Montefiore Medical Center and Assistant Professor of Medicine at Montefiore's Albert Einstein College of Medicine. She is a part of the division of gastrointestinal oncology and works closely with the multidisciplinary pancreatobiliary team.  She has worked closely with scientists at the Albert Einstein School of Medicine on translational studies in pancreatic cancer funded by PANCAN.  She is actively involved in the education of the medical oncology fellows.

She is board certified in internal medicine, hematology and oncology, and completed an internal medicine residency and a hematology/oncology fellowship at Albert Einstein College of Medicine after earning her medical degree at Northwestern University's Feinberg School of Medicine.

Alan Forsythe, Ph.D.

Dr. Forsythe has extensive experience in drug development management and statistical consulting.  He has served as Partner and President of Forsythe and Bear, LLC Biostatistical Consulting Firm since 2009 and as a member of the NIH/NCI Interoperability Workgroup in 2006.  He is a fellow of the American Statistical Association.

Dr. Forsythe held roles of increasing responsibility from 1991-2005 at Amgen, Inc., including as Vice President of Corporate Biomedical Information. There, he held direct responsibility for the Biostatistics, Epidemiology and Health Economics departments, and was responsible for planning, organizing and monitoring the implementation of new ways to increase profitability by shortening the time to get products to market around the world while improving the quality of the material presented to regulatory bodies for approval. He also had global oversight of long-range development plans for current and emerging Amgen products with respect to biometrics, epidemiology and health economics, and reviewed and approved all protocols for clinical studies, as well as proposed clinical publications and presentations.

Dr. Forsythe also previously served as Senior Vice President at Viratek, Inc., which is part of a $200 million pharmaceutical company, as Regional Director of Scientific Research at Southern California Kaiser Permanente Medical Group, as Adjunct Professor of Biomathematics at University of California at Los Angeles (UCLA) Medical School and as Adjunct Professor of Preventive Medicine at University of Southern California (USC). He has helped author more than 100 publications.